Sanwa Kagaku Kenkyusho Co., Ltd.

Other

Telik, Inc.

Takuji Kakigami

Yoshiro Ishiwata

Takahito Jomori

Shoji Yokochi

Kouji Matsushima

Hugo O Villar

Louise Robinson

Edgardo Laborde

Yukiharu Matsumoto

Fanying Meng

Brian T Peterson

Steven E Anuskiewicz

Hideaki Inagaki

Toshinao Usui

Yutaka Baba

Katsura Tsukamoto

Yoshiro Ozeki

Masayasu Kurono

Kiichi Sawai

Takahiko Mitani

Ryoichi Unno

Akira Tashita

Noriyuki Iwata

Nobuyuki Itoh

Yasuo Suzuki

Akira Hasegawa

Yasuaki Kondo

Kenji Miura

Kyoichi Asano

Masato Fukushima

Hiromoto Kimura

Mitsuru Oka

Masahiro Shirai

Yuji Hayashi

Masahiro Yoshida

Syoji Yokochi

Mitsuaki Takeuchi

Yukari Kobara

Hiroyuki Ohwaki

Motohiro Takeda

Nobuyuki Ito

Mitsuhiro Makino

Takao Igami

Hitoshi Hamashima

Yoshiro Ishiwatari

Yoshiharu Tsubamoto

Nobuyuki Asaeda

Tamaki Ohtuka

Kougaku Isogawa

Takayo Murase

Masao Sakairi

Toru Murase

Noriyasu Katoh

Takayo Yamamoto

A dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. A compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein Rand Reach represents hydrogen, an optionally substituted C1-6 alkyl group, or &#x2014;COORwhereupon Rrepresents hydrogen or an optionally substituted C1-6 alkyl group, or R, R, and a carbon atom together represent a 3- to 6-membered cycloalkyl group, Rrepresents hydrogen or an optionally substituted C6-10 aryl group, Rrepresents a hydrogen or a cyano group, D represents &#x2014;CONR-, &#x2014;CO&#x2014; or &#x2014;NRCO&#x2014;, Rrepresents hydrogen or an optionally substituted C1-6 alkyl group, E represents &#x2014;(CH)&#x2014; whereupon m is 1 to 3, &#x2014;CHOCH&#x2014;, or &#x2014;SCH&#x2014;, n is 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.

Compound inhibiting dipeptidyl peptidase IV

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

Antagonists of MCP-1 function and methods of use thereof

The present invention provides a low-molecular inhibitor of GIP functions and, further, an agent for preventing/ameliorating obesity based on inhibition of GIP functions, which comprises, as an active ingredient, a compound represented by the following general formula (I): (wherein Rrepresents hydrogen, halogen, a nitro group or a cyano group, Rand Reach represent hydrogen or halogen, hydrogen or a methoxy group, or both Rand Rmay form an optionally substituted benzene or pyrrole ring, and A represents nitrogen or C&#x2014;Rwhereupon Rrepresents hydrogen, an optionally substituted C1 to C6 alkyl group, &#x2014;OR, &#x2014;NRR, &#x2014;NHCO&#x2014;Ror &#x2014;SO&#x2014;Ror may, together with R, form an optionally substituted benzene or pyrrole ring, R, Rand Reach represent hydrogen or an optionally substituted C1 to C6 alkyl group, Rrepresents a C1 to C6 alkyl group or the like, and Rrepresents an optionally substituted morpholyl group or the like) or a pharmaceutically acceptable salt thereof.

Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

There are described sulfated and phosphated saccharide erivatives of the Formula ##STR1## wherein R.sub.1 is hydrogen atom or a residue of sulfate, phosphate or L-fucose; R.sub.2, R.sub.3 and R.sub.4 are hydrogen atom or a residue of sulfate or phosphate, respectively; 1 is an integer of 0 or 1;

Sulfated and phosphated saccharide derivatives, process for the

There are disclosed a 1-azabicyclo[3.3.0]octan derivative of the formula ##STR1## wherein n is an integer of 1-5; and Ar is an aromatic residue. a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof as hypermotility agents.

1-azabicyclo[3.3.0]octan derivative, salt thereof, process for the

There are disclosed a benzopyrancarboxamide derivative of the formula ##STR1## wherein R.sup.1 is hydrogen atom or a lower alkyl group; R.sup.2 is hydrogen atom, a lower alkyl group, halogen atom, an amino radical or an acylamino group; R.sup.3 is hydrogen atom, a lower alkyl group, a lower alkoxy group or halogen atom; dotted line is a possible double bond; and n is an integer of 1-5, and a pharmacologically acceptable salt of the compound, a process for the preparation of the compound and salt as well as use thereof.

Benzopyrancarboxamide derivatives, salts thereof, process for the

There are disclosed a benzo[b]furancarboxamide derivative of the formula ##STR1## wherein R.sup.a, R.sup.b, R.sup.c and R.sup.d are a hydrogen atom or lower alkyl group, respectively; R.sup.e is a hydrogen atom, amino radical, lower alkylamino group or acylamino group; X is a hydrogen atom or halogen atom; and n is an integer of 1-5, and including racemic compounds and stereo-isomers thereof, a salt of the compounds, a process for the preparation of the compounds and salts as well as use thereof for improving hypermotility.

Benzo[B]Furancarboxamide derivatives, process for the preparation of

The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Glycyrrhetinic acid derivatives

A process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives of the formula ##STR1## wherein X and Y are hydrogen atom, halogen atom or alkyl group, and R.sub.1 is hydrogen atom or alkyl group, intermediates thereof, as well as a process for the preparation of the intermediates.

Process for the preparation of optically active

Growing community of inventors

Inabe-gun, Japan

Takuji Kakigami